Heterozygous loss of Brca1 — mirroring germline BRCA1 mutations in humans — produces a striking paradox: female mice on a high-fat diet develop exacerbated obesity, hyperinsulinemia, and impaired glucose tolerance, while males show modest resistance to weight gain and improved glucose tolerance. Yet despite these diametrically opposed systemic phenotypes, both sexes converge on the same hepatic outcome: increased susceptibility to diet-induced steatosis. In females, this liver pathology involves transcriptional remodeling favoring lipid accumulation, oxidative stress responses, reduced mitochondrial complex IV activity, altered mitochondrial morphology, and lower hepatic ATP — a mechanistically rich picture. Human genetic data further associates BRCA1 variants with BMI, type 2 diabetes risk, and liver fat accumulation. Critically, tirzepatide (the dual GLP-1/GIP agonist) rescued both systemic and hepatic dysfunction in affected female mice.
This finding reframes BRCA1 biology in a clinically consequential way. The estimated 1-in-400 adults carrying a pathogenic BRCA1 variant are counseled primarily around cancer screening — metabolic surveillance is not standard practice. The hepatic convergence across sexes suggests a BRCA1-specific, sex-independent mechanism governing liver lipid homeostasis, possibly through mitochondrial bioenergetics rather than hormonal pathways. Limitations are meaningful: mouse models imperfectly model human BRCA1 haploinsufficiency, and the human genetic associations are observational. Still, the tirzepatide response offers a translatable therapeutic angle. This is an incremental-but-important paradigm expansion — positioning BRCA1 as a metabolic gene worthy of clinical monitoring protocols beyond oncology.
